What is Functional Neuromodulation?
Founded in 2010 by Dr. Andres Lozano, Functional Neuromodulation is a Toronto-based medical technology firm dedicated to advancing deep brain stimulation therapy. The company's core innovation involves the stimulation of the fornix to modulate neural activity in patients suffering from mild Alzheimer's disease. By leveraging a strategic partnership with Boston Scientific, FNM has successfully navigated the complexities of clinical development, moving from the foundational ADvance I Study to the current, multi-center ADvance II pivotal trial. This research is critical for establishing the efficacy and safety of DBS-f as a viable treatment option, effectively bridging the gap between experimental neuroscience and practical clinical application.
How much funding has Functional Neuromodulation raised?
Functional Neuromodulation has raised a total of $10.4M across 1 funding round:
Series A
$10.4M
Series A (2011): $10.4M with participation from Genesys Capital
Key Investors in Functional Neuromodulation
Genesys Capital
Genesys Capital is a Toronto-based venture capital firm focused on early-stage life sciences and healthcare companies, raising dedicated VC funds and investing in biotechnology and medical innovation across North America.
What's next for Functional Neuromodulation?
Looking ahead, the strategic focus for Functional Neuromodulation remains the successful execution and completion of the ADvance II study across the United States, Europe, and Canada. The company is poised to leverage its recent financing to accelerate patient enrollment and data collection, which are essential for regulatory approval processes. As the firm continues to refine its neuromodulation protocols, the integration of its technology into standard clinical practice could redefine the treatment paradigm for Alzheimer's. Future growth will likely depend on the company's ability to maintain its collaborative momentum with industry partners and navigate the evolving regulatory landscape for implantable medical devices.
See full Functional Neuromodulation company page
